Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + interferon-alfa-2b + leucovorin
- Development stage
- Unknown
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination regimen used in oncology, primarily investigated for advanced colorectal cancer and other solid tumors. The regimen combines the antimetabolite 5-fluorouracil (which inhibits thymidylate synthase, disrupting DNA synthesis), leucovorin (folinic acid, which enhances the cytotoxic effect of 5-FU by stabilizing its binding to thymidylate synthase), and interferon alfa-2b (a cytokine that modulates immune response and may augment the effects of chemotherapy). The combination was studied to determine if double modulation of 5-FU with both leucovorin and interferon alfa-2b could improve responses and survival compared to single modulation. However, clinical trials have shown that adding interferon alfa-2b increases toxicity without improving survival[1][4].
- Other names
- 5-FU + IFN-α2b + LV5-FU/IFN-α2b/LVFluorouracil and leucovorin with or without interferon alfa-2b
02
Targets
TS (Thymidylate synthase)
Beyond the preview
Go deeper on 5-fluorouracil + interferon-alfa-2b + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + interferon-alfa-2b + leucovorin.